

views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than July 12, 1999.

A. Federal Reserve Bank of Dallas
(W. Arthur Tribble, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Robert Cary McNair*, Houston, Texas; to acquire additional voting shares of Southwest Bancorporation of Texas, Inc., Houston, Texas, and thereby indirectly acquire additional voting shares of Southwest Bank of Texas, N.A., Houston, Texas.

Board of Governors of the Federal Reserve System, June 22, 1999.

Jennifer J. Johnson,
Secretary of the Board.

[FR Doc. 99-16284 Filed 6-25-99; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than July 12, 1999.

A. Federal Reserve Bank of New York (Betsy Buttrill White, Senior Vice President) 33 Liberty Street, New York, New York 10045-0001:

1. *Westdeutsche Landesbank Girozentrale*, Dusseldorf, Germany; to

acquire through its subsidiary, Criterion Investment Management, Houston, Texas, certain assets of Nicholas-Applegate Capital Management, Houston, Texas, and thereby engage in financial and investment advisory activities, pursuant to § 225.28(b)(6) of Regulation Y.

Board of Governors of the Federal Reserve System, June 22, 1999.

Jennifer J. Johnson,
Secretary of the Board.

[FR Doc. 99-16285 Filed 6-25-99; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 10:00 a.m., Friday, July 2, 1999.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Lynn S. Fox, Assistant to the Board; 202-452-3204.

SUPPLEMENTARY INFORMATION: You may call 202-452-3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of a bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.federalreserve.gov> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: June 24, 1999.

Jennifer J. Johnson,
Secretary of the Board.

[FR Doc. 99-16560 Filed 2-24-99; 3:42 pm]

BILLING CODE 6210-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention, Food and Drug Administration, and National Institutes of Health

Development of a Public Health Action Plan to Combat Antimicrobial Resistance

The Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Institutes of Health (NIH) announce an open meeting concerning antimicrobial resistance.

Name: Development of a Public Health Action Plan to Combat Antimicrobial Resistance.

Times and Dates: 10:30 a.m.-6 p.m., July 19, 1999. 8a.m.-6 p.m., July 20, 1999. 8a.m.-3:30 p.m., July 21, 1999.

Place: Sheraton Atlanta Hotel, 165 Courtland at International Boulevard, Atlanta, Georgia 30303.

Status: Open to the public, limited only by the space available.

Purpose: To solicit input from invited consultants regarding items to be included in a Public Health Action Plan that, when published, will serve as a blueprint for activities of Federal agencies to combat antimicrobial resistance. The Plan is being developed by a Task Force composed of Federal personnel from several Federal agencies and departments, co-chaired by CDC, FDA, and NIH. The focus of the Plan will be on domestic activities.

Matters To Be Discussed: The agenda will focus on the following topics related to antimicrobial resistance:

1. Surveillance
2. Prevention and control
3. Research
4. Product development

Comments and suggestions from the consultants for specific action items for Federal agencies related to each of these topics will be taken under advisement by the task force. The Task Force may also utilize other sources of information in developing the Action Plan. The agenda does not include development of consensus positions, guidelines, or discussions or endorsements of specific commercial products.

Agenda items are subject to change as priorities dictate.

Limited time will be available for oral comments and suggestions from the public. Written comments and suggestions from the public are encouraged and should be received by the contact person listed below by August 22, 1999.

Persons anticipating attending the meeting are requested to send written notification by July 12, 1999, including name, organization (if applicable), address, phone, fax, and email addresses to the contact below.

FOR FURTHER INFORMATION

CONTACT: Minnie Johnson, Antibiotic Resistance, NCID, CDC, M/S C-20, 1600 Clifton Road, NE, Atlanta, Georgia 30333, telephone 404/639-2603, fax 404/639-4139, E-mail: mlj2@cdc.gov.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: June 21, 1999.

Carolyn J. Russell,

Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99-16298 Filed 6-25-99; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Centers for Disease Control and Prevention****Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Cooperative Agreements for Prevention Research Centers**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Cooperative Agreements for Prevention Research Centers, Program Announcement #98047, meeting.

Times and Dates:

9 a.m.-5 p.m., July 12, 1999 (Closed).
8 a.m.-9 a.m., July 13, 1999 (Open).
9 a.m.-5 p.m., July 13, 1999 (Closed).
8 a.m.-5 p.m., July 14, 1999 (Closed).
8 a.m.-5 p.m., July 15, 1999 (Closed).
8 a.m.-5 p.m., July 16, 1999 (Closed).

Place: Sheraton Colony Square Hotel, 188 14th St., NE, Atlanta, GA. Telephone 404/892-6000.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Public Law 92-463.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement #98047.

This notice is being published less than 15 days prior to the meeting, due to administrative delays.

Contact Person for More Information: Marshall Kreuter, Ph.D., Associate Director for Health Promotion, Policy and Program Development, Division of Adult and

Community Health, National Center for Chronic Disease Prevention and Health Promotion, 3005 Chamblee Tucker Rd., Atlanta, GA., 30341-4133. Telephone 770/488-5832. E-mail *mak2@cdc.gov*.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: June 21, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention CDC.

[FR Doc. 99-16297 Filed 6-25-99; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration****Arthritis Advisory Committee; Notice of Meeting**

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Arthritis Advisory Committee.

General Function of the Committee:

To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on July 21, 1999, 8 a.m. to 5 p.m.

Location: Holiday Inn, Walker/Whetstone Salons, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Kathleen R. Reedy or LaNise S. Giles, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, or email *reedyk@cder.fda.gov* or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12532. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss the evidence needed to establish that a drug product has a beneficial effect on joint structure in patients with osteoarthritis.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending

before the committee. Written submissions may be made to the contact person by July 12, 1999. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 noon. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 12, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: June 18, 1999.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 99-16314 Filed 6-25-99; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration****Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting**

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee:

To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on July 26, 1999, 10:30 a.m. to 5 p.m., and July 27, 1999, 7:30 a.m. to 2:30 p.m.

Location: Hilton Hotel, Salons B and C, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Hany W. Demian or Mark N. Melkerson, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2036, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12521. Please call the Information Line for up-to-date information on this meeting.